Diopsys

Montville, United States Founded: 2002 • Age: 24 yrs Acquired By LumiThera
Non-invasive visual electrophysiology devices are supplied for ophthalmological diagnosis.
Request Access

About Diopsys

Diopsys is a company based in Montville (United States) founded in 2002 was acquired by LumiThera in November 2021.. Diopsys has raised $1.05 million across 1 funding round from investors including LumiThera. The company has 31 employees as of December 31, 2021. Diopsys offers products and services including NOVA Vision Testing System, VEP, and ERG. Diopsys operates in a competitive market with competitors including Sensimed, i-Optics, Azul Optics, Oxymap and Bioptigen, among others.

  • Headquarter Montville, United States
  • Employees 31 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Diopsys, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.05 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.05 M (USD), Seed

    Oct 17, 2019

  • Investors
  • Employee Count
    31

    as on Dec 31, 2021

  • Acquired by
    LumiThera

    (Nov 11, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Diopsys

Diopsys offers a comprehensive portfolio of products and services, including NOVA Vision Testing System, VEP, and ERG. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

System for advanced vision testing and diagnostics in healthcare settings.

Technology for visual evoked potential testing in select countries.

Electroretinography device for eye function assessment outside the US.

People of Diopsys
Headcount 10-50
Employee Profiles 7
Employee Profiles
People
Joseph Fontanetta
CEO
People
Alan F Rich
Vice President, Sales
People
Tibor Szoke
Director of Manufacturing
People
John Morise
District Manager

Unlock access to complete

Funding Insights of Diopsys

Diopsys has successfully raised a total of $1.05M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.05 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Seed — $1.0M
  • First Round

    (17 Oct 2019)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2019 Amount Seed - Diopsys Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Diopsys

Diopsys has secured backing from 1 investor. Prominent investors backing the company include LumiThera. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Photobiomodulation treatments for ocular diseases are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Diopsys

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Diopsys

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Diopsys Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Diopsys

Diopsys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sensimed, i-Optics, Azul Optics, Oxymap and Bioptigen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
A contact lens-based platform for glaucoma monitoring is offered.
domain founded_year HQ Location
i-Optics specializes in providing advanced retina and cornea imaging systems for medical professionals.
domain founded_year HQ Location
Device for assessing the eye health against damaging light
domain founded_year HQ Location
Retinal Imaging technology to assess retinal oxygen saturation and vessel width
domain founded_year HQ Location
Spectral domain OCT devices for ophthalmic imaging are developed.
domain founded_year HQ Location
Portable technologies for multifocal eye corrections before surgeries are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Diopsys

Frequently Asked Questions about Diopsys

When was Diopsys founded?

Diopsys was founded in 2002 and raised its 1st funding round 17 years after it was founded.

Where is Diopsys located?

Diopsys is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.

Is Diopsys a funded company?

Diopsys is a funded company, having raised a total of $1.05M across 1 funding round to date. The company's 1st funding round was a Seed of $1.05M, raised on Oct 17, 2019.

How many employees does Diopsys have?

As of Dec 31, 2021, the latest employee count at Diopsys is 31.

What does Diopsys do?

Diopsys is a provider of non-invasive office-based visual electrophysiology medical devices that help ophthalmologists and optometrists analyze the entire visual pathway for visual and neuro-visual disorders. The company provides both Visual Evoked Potential (VEP) and Electroretinography (ERG) vision testing technology. Diopsys, Inc.s medical devices include the Diopsys NOVA and Diopsys ARGOS ERG and VEP Vision Testing System product series and the Enfant Pediatric VEP Vision Testing System.

Who are the top competitors of Diopsys?

Diopsys's top competitors include 2EyesVision, Sensimed and Azul Optics.

What products or services does Diopsys offer?

Diopsys offers NOVA Vision Testing System, VEP, and ERG.

Who are Diopsys's investors?

Diopsys has 1 investor. Key investors include LumiThera.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available